Format

Send to

Choose Destination
Pigment Cell Melanoma Res. 2017 Jan;30(1):28-40. doi: 10.1111/pcmr.12561.

Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference.

Author information

1
National Skin Centre, Singapore City, Singapore.
2
Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.
3
Dermatology Department, Cairo University, Cairo, Egypt.
4
Multicultural Dermatology Center, Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.
5
Department of Dermatology, University Hospital of Nice, Nice, France.
6
INSERM U1065, Team 12, C3M, Nice, France.
7
Department of Dermatology, University of Münster, Münster, Germany.
8
Dermatology Department, Minia University, Minia, Egypt.
9
Skin Physicians, Mount Elizabeth Medical Center, Singapore City, Singapore.
10
Department of Dermatology, Kaohsiung Medical University Hospital and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
11
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.
12
Photomedicine Institute, Vancouver Coastal Health Research Institute, Vancouver, BC, Canada.
13
Department of Dermatology & Venereology, All India Institute of Medical Sciences, New Delhi, India.
14
Suite 202, Westville Hospital, Westville, South Africa.
15
Department of Dermatology Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
16
Department of Dermatology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
17
Department of Dermatology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
18
Department of Dermatology, Newton Wellesley Hospital, Newton, MA, USA.
19
Department of Dermatology, Ghent University Hospital, Ghent, Belgium.
20
National Center for Vitiligo and Psoriasis, Riyadh, Saudi Arabia.
21
Mulekar Clinic, Mumbai, India.
22
Division of Dermatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
23
Department of Dermatology, University of New South Wales, Sydney, NSW, Australia.
24
Skin and Cancer Foundation, Darlinghurst, NSW, Australia.
25
Beecroft Dermatology, Beecroft, Sydney, NSW, Australia.
26
Mohammed V University in Rabat, Department of Dermatology, Ibn Sina University Hospital, Rabat, Morocco.
27
Pigmentary Disorders Outpatient Clinic, Bordeaux, France.
28
Department of Dermatology, Fiona Stanley Hospital and University of Western Australia, Perth, WA, Australia.
29
Department of Dermatology, Pontifícia Universidade Católica do Paraná, Curitiba, Brazil.
30
Dermatology, Andrology & Venereology Department, Ain Shams University, Cairo, Egypt.
31
Department of Dermatology, Academic Medical Centre, Netherlands Institute for Pigment Disorders, University of Amsterdam, Amsterdam, The Netherlands.
32
Department of Dermatology and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France.
33
INSERM U 1035, University of Bordeaux, Bordeaux, France.
34
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
35
Department of Dermatology, Hôpital Henri Mondor, Créteil, France.
36
EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris-Est Créteil, Créteil, France.
37
Cutaneous pathophysiology, San Gallicano Dermatologic Institute IRCCS, Rome, Italy.

Abstract

The Vitiligo Global Issues Consensus Conference (VGICC), through an international e-Delphi consensus, concluded that 'repigmentation' and 'maintenance of gained repigmentation' are essential core outcome measures in future vitiligo trials. This VGICC position paper addresses these core topics in two sections and includes an atlas depicting vitiligo repigmentation patterns and color match. The first section delineates mechanisms and characteristics of vitiligo repigmentation, and the second section summarizes the outcomes of international meeting discussions and two e-surveys on vitiligo repigmentation, which had been carried out over 3 yr. Treatment is defined as successful if repigmentation exceeds 80% and at least 80% of the gained repigmentation is maintained for over 6 months. No agreement was found on the best outcome measure for assessing target or global repigmentation, therefore highlighting the limitations of e-surveys in addressing clinical measurements. Until there is a clear consensus, existing tools should be selected according to the specific needs of each study. A workshop will be conducted to address the remaining issues so as to achieve a consensus.

KEYWORDS:

outcome measure; pigment; repigmentation; repigmentation pattern; vitiligo

PMID:
27864868
DOI:
10.1111/pcmr.12561
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center